What: A study in Obstetrics & Gynecology examined over 3,000 women who had “high grade cervical dysplasia,” a.k.a. abnormal cells that have a higher likelihood of developing into cervical cancer. They found that less than half (45%) got the follow-up testing recommended in the 30 months after treatment.

Key line: “Approximately half of patients did not receive guideline-concordant surveillance after treatment for high-grade dysplasia, and one-third had a subsequent abnormal co-test result. Patients with high-grade cervical dysplasia are at elevated risk of subsequent abnormalities and should continue to be closely monitored. Additional systematic monitoring is needed to ensure guideline-compliant surveillance after dysplasia treatment.”

Source: Obstetrics & Gynecology